• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Fluorobenzenes

Recent Advances in the Synthesis and Applications of 1-(2,5-Difluorophenyl)ethan-1-ol (CAS: 3874-31-5)

1-(2,5-Difluorophenyl)ethan-1-ol (CAS: 3874-31-5) is a fluorinated aromatic alcohol that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications as a building block in drug synthesis and its potential biological activities. Recent studies have focused on optimizing its synthetic routes, exploring its pharmacological properties, and investigating its role in the development of novel therapeutic agents. This research brief provides an overview of the latest advancements related to this compound, highlighting key findings from recent publications and industry reports.

One of the primary areas of research has been the development of efficient and scalable synthetic methods for 1-(2,5-difluorophenyl)ethan-1-ol. A 2023 study published in the Journal of Organic Chemistry demonstrated a novel catalytic asymmetric reduction of 2,5-difluoroacetophenone using chiral ruthenium complexes, achieving high enantioselectivity (up to 98% ee) and yield (92%). This method addresses previous challenges in stereocontrol and offers a greener alternative to traditional reducing agents. The study also emphasized the importance of this chiral intermediate in the synthesis of fluorinated pharmaceuticals, such as protease inhibitors and kinase modulators.

In addition to synthetic improvements, recent investigations have explored the biological activities of 1-(2,5-difluorophenyl)ethan-1-ol and its derivatives. A 2024 preprint in Bioorganic & Medicinal Chemistry Letters reported that fluorinated analogs derived from this compound exhibit promising inhibitory effects against SARS-CoV-2 main protease (M^pro), with IC₅₀ values in the low micromolar range. Molecular docking studies revealed that the difluorophenyl moiety enhances binding affinity to the protease's active site, suggesting its potential as a scaffold for antiviral drug design.

Furthermore, industry applications of 1-(2,5-difluorophenyl)ethan-1-ol have expanded, particularly in agrochemicals. A patent filed by a leading agrochemical company in early 2024 disclosed its use as a key intermediate in the synthesis of next-generation herbicides targeting resistant weed species. The patent highlights the compound's stability under environmental conditions and its role in improving the efficacy of fluorinated herbicidal agents.

In conclusion, recent research on 1-(2,5-difluorophenyl)ethan-1-ol (CAS: 3874-31-5) underscores its growing importance in both pharmaceutical and agrochemical industries. Advances in asymmetric synthesis, coupled with emerging biological insights, position this compound as a valuable tool for drug discovery and development. Future studies are expected to delve deeper into its mechanistic roles and explore additional therapeutic applications, particularly in infectious diseases and oncology.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)